Reduced-Dose Schedule of Cabazitaxel Viable for Seniors With mCRPC
A reduced-dose schedule of cabazitaxel (Jevtana) plus prophylactic granulocyte colony-stimulating factor (G-CSF) should be offered to older men with metastatic castration-resistant prostate cancer (mCRPC), according to results from the phase III randomized CABASTY trial. Rates of grade 3 or higher neutropenia or neutropenic complications were about 12 times lower with biweekly cabazitaxel 16 mg/m2 plus […]